These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8248919)

  • 1. Reduction by niceritrol treatment of serum lipoprotein(a) in normolipidemic patients with coronary artery disease.
    Sano R; Fujino A; Saito T; Takenaka K; Yahata Y; Ogyu A; Toyota T
    Tohoku J Exp Med; 1993 Apr; 169(4):299-307. PubMed ID: 8248919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-dependent effect of niceritrol on plasma lipoprotein-a.
    Teramoto T; Yamada N; Shimano H; Oka Y; Itakura H; Saito Y; Morisaki N; Shirai K; Ishikawa T; Tada N; Ito H; Yamanouchi T; Matsushima T; Kawakami M; Murase T; Okubo M; Totsuka Y; Kikuchi M
    Scand J Clin Lab Invest; 1996 Jul; 56(4):359-65. PubMed ID: 8837243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of niceritrol on fibrinolysis and lipoprotein (a) levels in patients with coronary artery disease.
    Suefuji H; Ogawa H; Yasue H; Imoto N; Sakamoto T; Miyao Y; Kaikita K; Soejima H; Nishiyama K
    Coron Artery Dis; 1996 Feb; 7(2):167-72. PubMed ID: 8813450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of niceritrol on serum lipoprotein(a) and lipids in patients with high levels of lipoprotein(a).
    Yamauchi K; Tanahashi Y; Okada M; Tsuzuki J; Sato A; Abe K; Inagaki H; Agetsuma H; Hattori R; Izawa H
    Clin Ther; 1995; 17(1):52-9. PubMed ID: 7758061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of niceritrol on levels of serum lipids, lipoprotein(a), and fibrinogen in patients with primary hypercholesterolemia.
    Matsunaga A; Handa K; Mori T; Moriyama K; Hidaka K; Yuki M; Sasaki J; Arakawa K
    Atherosclerosis; 1992 Jun; 94(2-3):241-8. PubMed ID: 1385959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pentaerythritol tetranicotinate (niceritrol) decreases plasma lipoprotein(a) levels.
    Tanaka K; Hayashi K; Shingu T; Kuga Y; Okura Y; Yasunobu Y; Ohtani H; Nomura S; Kurushima H; Saeki M; Kambe M; Kajiyama G
    Metabolism; 1997 Apr; 46(4):355-8. PubMed ID: 9109834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Niceritrol reduces plasma lipoprotein(a) levels in patients undergoing maintenance hemodialysis.
    Nakahama H; Nakanishi T; Uyama O; Sugita M; Miyazaki M; Yokokawa T; Okamura K; Tanaka Y; Shirai D
    Ren Fail; 1993; 15(2):189-93. PubMed ID: 8469786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease.
    Vessby B; Lithell H; Gustafsson IB; Borberg J
    Atherosclerosis; 1979 Aug; 33(4):457-77. PubMed ID: 228684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
    Sasaki J; Yamamoto K; Kobori S; Setoguchi Y; Sato Y; Matsunaga A; Shichiri M; Sakai T; Kono S; Arakawa K
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of combined treatment with L-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus.
    Solfrizzi V; Capurso C; Colacicco AM; D'Introno A; Fontana C; Capurso SA; Torres F; Gadaleta AM; Koverech A; Capurso A; Panza F
    Atherosclerosis; 2006 Oct; 188(2):455-61. PubMed ID: 16384561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial.
    Owada A; Suda S; Hata T
    Am J Med; 2003 Apr; 114(5):347-53. PubMed ID: 12714122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease.
    Tsimikas S; Brilakis ES; Miller ER; McConnell JP; Lennon RJ; Kornman KS; Witztum JL; Berger PB
    N Engl J Med; 2005 Jul; 353(1):46-57. PubMed ID: 16000355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the nicotinic acid analogue niceritrol on lipoprotein Lp(a) and coagulation-fibrinolysis status in patients with chronic renal failure on hemodialysis.
    Shoji T; Nishizawa Y; Kawasaki K; Tabata T; Matsushita Y; Inoue T; Morii H
    Nephron; 1997; 77(1):112-3. PubMed ID: 9380227
    [No Abstract]   [Full Text] [Related]  

  • 14. [Plasma nicotinic acid levels in hemodialysis patients after the administration of niceritrol].
    Saika Y; Kodama N; Kimura K; Fujii R; Ohtani H; Mune M; Mimura K; Maeda T; Yukawa S
    Nihon Jinzo Gakkai Shi; 1999 Jun; 41(4):430-5. PubMed ID: 10441992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial.
    Alaupovic P; Fesmire JD; Hunnighake D; Domanski M; Forman S; Knatterud GL; Forrester J; Herd JA; Hoogwerf B; Campeau L; Gobel FL
    Atherosclerosis; 1999 Oct; 146(2):369-79. PubMed ID: 10532693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of niceritrol (pentaerythritol tetranicotinate) on plasma lipoprotein concentration: increment of high density lipoprotein(HDL) cholesterol and HDL-cholesterol/low density lipoprotein cholesterol ratio in hypo-high density lipoproteinemia.
    Oida K; Nakai T; Tamai T; Kutsumi Y; Kobayashi T; Hayashi T; Yamada S; Takeda R
    Artery; 1982; 10(4):266-85. PubMed ID: 7181672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein(A): physiologic function, association with atherosclerosis, and effects of lipid-lowering drug therapy.
    Spinler SA; Cziraky MJ
    Ann Pharmacother; 1994 Mar; 28(3):343-51. PubMed ID: 8193425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic determinants of the course of coronary artery disease in men.
    Watts GF; Mandalia S; Slavin BM; Brunt JN; Coltart DJ; Lewis B
    Clin Chem; 1994 Dec; 40(12):2240-6. PubMed ID: 7988012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The lipoprotein fraction between VLDL and LDL detected by biphasic agarose gel electrophoresis reflects serum remnant lipoprotein and Lp(a) concentrations.
    Sato I; Taniguchi T; Ishikawa Y; Kusuki M; Hayashi F; Mukai M; Kawano S; Kondo S; Yamashita S; Kumagai S
    J Atheroscler Thromb; 2006 Feb; 13(1):55-61. PubMed ID: 16505592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time course of serum Lp(a) in men after coronary artery bypass grafting.
    Cobbaert C; Sergeant P; Meyns B; Szécsi J; Kesteloot H
    Acta Cardiol; 1992; 47(6):529-42. PubMed ID: 1290314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.